share_log

HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $73

HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $73

HC Wainwright & Co.維持對SpringWorks Therapeutics的買入,將目標股價提高至73美元
Benzinga ·  2023/11/29 06:50

HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the price target from $64 to $73.

HC Wainwright & Co. 分析師羅伯特·伯恩斯維持SpringWorks Therapeutics(納斯達克股票代碼:SWTX)的買入,並將目標股價從64美元上調至73美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論